ClinicalTrials.gg
RecruitingNCT06324721LymphSensUpdated Jan 29, 2025

Who and Why do Patients Report Lymphedema After Breast Cancer Treatment Without an Objective Measurable Swelling

An interventional study of Measurements for breast cancer related lymphedema (volumetric measurements, bioimpedance spectroscopy, bioimpedance analysis, tissue dielectric constant measurements, ultrasonography) and Measurements for lymphatic problems (volumetric measurements, tissue dielectric measurement, lymphofluoroscopy) in Breast Cancer, Lymphedema and Sensory Processing Disorder, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven — 7 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · Universitaire Ziekenhuizen KU Leuven.

Planned enrollment
2nd of 21
230 · median 100
Started
2024
with 1 other
No phase
13 of 31
4 open now
Registered
28th of 31
by date

Among the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 with no phase, and was the 28th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

Breast cancer related lymphedema (BCRL) at the arm and/or trunk is an extremely dreaded complication after breast cancer treatment due to its chronicity and impact.

The incidence of objective arm and trunk/ breast BCRL is declining due to the major shift into the treatment approach of breast cancer. However, many patients report a sensation of swelling without the presence of objective BCRL, referred to as subjective BCRL. Therefore, subjective BCRL is defined as the diagnosis of BCRL based on the patient's sensation of a difference in size at the arm and/or trunk without the presence of objective BCRL.

At this moment, there is no clear information on the prevalence and the transitions between different BCRL states (no-subjective-objective) over time, as well as about the underlying mechanisms and contributing factors of subjective BCRL. Therefore, the investigators hypothesize that four mechanisms might be associated with the presence and severity of subjective arm or trunk/breast BCRL, including the presence and/ or severity of lymphatic (1) and sensory processing problems (nociceptive (2), neuropathic (3), and/or central sensory processing problems (4)).

The investigators will set up a prospective longitudinal study with breast cancer patients to determine the prevalence of subjective and objective arm or trunk/ breast BCRL at 1, 6, and 12 month(s) post-surgery and the transitions between different BCRL states (no-subjective-objective BCRL) (AIM 1). In addition, factors related to four potential underlying mechanisms (lymphatic, nociceptive, neuropathic, and central sensory processing problems) that contribute to the occurrence of subjective BCRL in comparison to no self-reported swelling and objective BCRL will be determined (AIM 2). Furthermore, the present study will be undertaken to determine factors related to these four underlying mechanisms that contribute to the severity of subjective BCRL at arm or trunk/ breast BCRL within the group of patients with subjective BCRL at different time-points after surgery (at 1, 6, and 12 month(s) post-surgery) (AIM 3).

03

Conditions studied

  • Breast Cancer
  • Lymphedema
  • Sensory Processing Disorder

Keywords

  • lymphedema
  • subclinical edema
  • nociceptive problems
  • neuropathic problems
  • central sensory problems
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. adults (men and women) who are ≥ 18 years of age
  2. diagnosed with primary unilateral non- or oligometastatic breast cancer
  3. scheduled for surgery (mastectomy or breast conserving surgery; in combination with axillary lymph node dissection or sentinel node )
  4. able to read, understand, and speak Dutch
  5. have voluntary written of the patient

Exclusion criteria

Exclusion Criteria:

  1. distant
  2. planned bilateral lymph node surgery
  3. oedema of the arm from another cause
  4. an allergy to iodine or Indocyanine Green (ICG), or
  5. physically or mentally unable to participate throughout the entire duration of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Breast cancer patients

    Women and men who are being diagnosed with primary unilateral non-metastatic or oligometastatic breast cancer and scheduled for breast surgery in combination with axillary lymph node dissection or sentinel node biopsy

    Other: Measurements for breast cancer related lymphedema (volumetric measurements, bioimpedance spectroscopy, bioimpedance analysis, tissue dielectric constant measurements, ultrasonography) · Other: Measurements for lymphatic problems (volumetric measurements, tissue dielectric measurement, lymphofluoroscopy) · Other: Measurements for sensory processing problems by monofilaments, algometer, goniometer, and neurosensory analyzer

Interventions

  • OtherMeasurements for breast cancer related lymphedema (volumetric measurements, bioimpedance spectroscopy, bioimpedance analysis, tissue dielectric constant measurements, ultrasonography)

    Assessments related to different types of breast cancer related lymphedema at arm (1. self-reported swelling at arm, 2. subjective arm lymphedema, 3. objective arm lymphedema) using the Norman questionnaire, volume measurements (volumetry and perimetry), bioimpedance spectroscopy, and bioimpedance analysis Assessments related to different types of breast cancer related lymphedema at trunk/ breast (1. self-reported swelling at trunk/ breast, 2. subjective trunk/ breast lymphedema, 3. objective trunk/ breast lymphedema) using the Norman questionnaire, tissue dielectric measurements, and ultrasonography

  • OtherMeasurements for lymphatic problems (volumetric measurements, tissue dielectric measurement, lymphofluoroscopy)

    Clinical assessments related to lymphatic problems (1. amount of swelling at arm by relative arm volume difference, 2. amount of swelling at trunk by percentage water ratio, 3. severity of dermal rerouting at upper limb and trunk by lymphofluoroscopy (i.e., near-infrared fluorescence imaging device)

  • OtherMeasurements for sensory processing problems by monofilaments, algometer, goniometer, and neurosensory analyzer

    Clinical measurements related to nociceptive, neuropathic and central sensory problems based on the Quantitative Sensory Testing principles using different devices algometer, goniometer, standardized set of monofilaments, and neurosensory analyzer

06

What researchers measure

Primary outcomes

  1. Presence of subjective arm lymphedema

    The presence of subjective arm lymphedema will be determined by the combination of two items. If self-reported swelling at arm is "yes" and objective arm BCRL is "no", then the presence of subjective arm BCRL will be defined as yes. To determine the presence of self-reported swelling at arm, we will use the Norman Questionnaire. If the patient responds ''yes'' to the item self-reported difference in the sizes of at least one of 3 sites (hand, lower arm, and upper arm), the presence of 'self-reported swelling at arm' is recorded as ''yes''. To determine the presence of objective lymphedema at arm, please see outcome 3. Unit of the outcome measure is yes/no. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  2. Presence of subjective trunk/ breast lymphedema

    The presence of subjective trunk/ breast lymphedema will be determined by the combination of two items. If self-reported swelling at trunk/ breast is "yes" and objective trunk/ breast BCRL is "no", then the presence of subjective trunk/ breast BCRL will be defined as yes. To determine the presence of self-reported swelling at trunk/ breast, we will use the Norman Questionnaire. If the response is ''yes'' to the item self-reported difference in the sizes of at least one of these 2 sites (trunk or breast region), the presence of ''self-reported swelling in the trunk/breast'' is recorded as ''yes.'' Unit of the outcome measure is yes/no. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  3. Presence of objective arm lymphedema

    4 methods are used to determine the presence of objective arm lymphedema: a) relative hand volume difference, b) relative arm volume difference, c) bioimpedance analysis, and d) bioimpedance spectroscopy at arm region If at least one of four cut-off values is present, the presence of objective arm lymphedema will be considered as yes: 1. an increase of relative hand volume difference between the affected and non-affected hands of ≥5% compared to the baseline difference OR 2. an increase of relative arm volume difference between the affected and non-affected arms of ≥5% compared to the baseline difference OR 3. Extra-cellular water ratio by Bioimpedance Analysis at affected arm of \>0.3850 OR 4. Extracellular water ratio by Bioimpedance Spectroscopy, \>6.5 change in the L-Dex score from the baseline score Unit of the outcome measure is yes/no. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  4. Presence of objective trunk/ breast lymphedema

    2 methods are used to determine the presence of objective trunk/breast lymphedema: a) tissue dielectric measurement, b) skin thickness measurement at trunk/breast region If one of four criteria is present, the presence of objective trunk/ breast lymphedema will be considered as yes: 1. percentage of water content ratio at the trunk ≥ 1.32 OR 2. percentage of water content ratio at the trunk ≥ 1.40 OR 3. \> 2 standard deviations (SD) from the average skin thickness in at least one reference point on the trunk compared to the reference value at pre-surgery OR 4. \> 2 SD from the average skin thickness in at least one reference point one quadrant of the affected breast compared to the reference value at pre-surgery Unit of the outcome measure is yes/no. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

Secondary outcomes

  1. Amount of swelling at upper limb and trunk/breast

    See outcomes 3 and 4 Presence of objective arm and trunk/ breast BCRL Total upper limb (hand + arm) volume is calculated by taking the sum of the hand volume and relative arm volume. Then, the difference between both upper limb is calculated. Relative upper limb volume difference is used for analysis. Average percentage water (PWC) value of reference points is calculated. PWC ratio=PWC affected side at post-surgery/PWC reference value at baseline is used for analysis. Assessment at pre-surgery, 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  2. Severity of dermal rerouting at upper limb and trunk/breast

    Lymphofluoroscopy will be used. Indocyanine green (ICG)/ aqua is injected in the patient's hand; linear (normal) and dermal rerouting patterns are visualized after 90 minutes of the injection. The body is divided into 14 areas (11 areas at upper limb and 3 areas at trunk/breast). Each area is scored between 0 and 3: 0 (normal pattern), 1 (splash pattern), 2 (stardust pattern), and 3 (diffuse pattern). Total dermal rerouting score for arm is between 0 and 33. Total dermal rerouting score for trunk/ breast is between 0 and 9. Assessment at 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  3. Severity of myofascial adhesions at the level of the scars

    The evaluation tool for Myofascial Adhesions in Patients after Breast Cancer (MAP-BC evaluation tool): assessed at 2 locations (i.e., axillary scar and breast or mastectomy scar). Each location is palpated for adhesions at 3 levels (i.e., skin, superficial, and deep) on a 4-points scale (0- no restriction, 1-limited restriction, 2-early and hard restriction, and 3-very stiff and tissue gliding is not possible). The total score of the MAP-BC is calculated by taking the sum of each item and is used for the analysis Total score ranges between 0 - 18. Assessment at 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  4. Severity of local muscle stiffness

    Myofascial tissue stiffness will be evaluated at the affected and non-affected sides of the pectoralis major, infraspinatus, and teres major muscles. Average muscle stiffness score of 3 muscles at affected and non-affected side is calculated. Then, the local muscle stiffness ratio is calculated: Average muscle stiffness at the affected side in N/m/Average muscle stiffness at the non-affected side and this ratio is used for the analysis. Unit of the outcome measure is Newton/ meter. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  5. Severity of local muscle tenderness

    Pressure pain thresholds will be evaluated using digital algometer on affected and non-affected sides of pectoralis major, infraspinatus, and teres major muscles. Increasing pressure (1kg/sec) is applied perpendicularly to the skin. Patient is asked to say 'stop' when the sensation of pressure first changes to unpleasant feeling. 2 measurements are taken at each reference point. Average pressure pain thresholds of 2 measurements at affected and non-affected side is calculated. The local muscle tenderness ratio is calculated: Average pressure pain thresholds at the affected side/ average pressure pain thresholds at the non-affected side and this ratio is used for the analysis. Unit of the outcome measure is kilogram per square centimeter (kg/cm2). Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  6. Severity of impaired shoulder range of motion

    Arm abduction range is evaluated by the digital goniometer. Patient is instructed to perform one shoulder abduction movement with full elbow extension and neutral wrist flexion/extension in the standing position. Ratio of affected shoulder abduction range of motion/non-affected shoulder abduction range of motion is calculated and used for the analysis. Unit of the outcome measure is degree. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  7. Presence of neuropathic pain at upper arm and trunk

    The presence of neuropathic pain at upper arm and trunk will be evaluated by the Douleur neuropathique en 4 questions (DN4). DN4 consists of interview and examination parts. Interview part: seven items about pain descriptors. Examination part: three items about the hypoesthesia to touch and pinprick, and the presence of hyper-esthesia by the application of brushing. Total score ranges between 0 - 10. The presence of neuropathic pain is "yes" if the total score of DN4 is ≥4 . Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  8. Severity of sensory loss at the arm and trunk

    Mechanical detection thresholds will be determined by using standardized set of 12 nylon monofilaments at affected inner upper arm and lateral trunk. Mechanical detection threshold is defined as the lowest mechanical force identified by the patient and determined based on the principles of the Quantitative Sensory Testing. Two measurements are obtained at the affected inner upper arm and the lateral trunk. Geometric mean of the first and second detected stimulus is obtained for each location and used for the analysis. Average mechanical detection threshold score is between 0.25 - 512 millinewton (mN). Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  9. Severity of altered cold sensation sensitivity at the arm and trunk

    Cold sensation sensitivity is assessed by the Thermotest device (TSA-2 Neurosensory Analyser) at affected inner upper arm and lateral trunk. The patient pushes the button when she/he experiences a change from a thermo-neutral state to a distinct cold sensation. 3 repetitions are obtained. Average score for cold sensation sensitivity is calculated from all measurements at each assessment location. Unit of the outcome measure is centigrade degree. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  10. Severity of altered heat sensation sensitivity at the arm and trunk

    Heat sensation sensitivity is assessed by the Thermotest device (TSA-2 Neurosensory Analyser) at affected inner upper arm and lateral trunk. The patient pushes the button when she/he experiences a change from a thermo-neutral state to a distinct heat sensation. 3 repetitions are obtained. Average score for heat sensation sensitivity is calculated from all measurements at each assessment location. Unit of the outcome measure is centigrade degree. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  11. Severity of altered sensory acuity in the arm and trunk

    Sensory acuity will be evaluated using aesthesiometer at the affected inner side of upper arm and lateral side of the trunk. A stimulus is given with one or two pins on the skin of the inner side of affected upper arm and lateral side of the trunk. Patient indicates whether she/he feels one or two points. Average score of two measurements is calculated. Score is between 0 - 100 millimeter. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  12. Severity of widespread hyperalgesia

    Heat pain threshold is assessed by the Thermotest device (TSA-2 Neurosensory Analyser). Heat pain threshold is measured on the affected side at the inner upper arm and lateral trunk, and on the non-affected side at the tibialis anterior. The patient presses a button when the heat sensation is first perceived as unpleasant. 3 measurements are obtained, and the average heat pain threshold score is calculated for each assessment location. A normalized ratio is then calculated, with a higher ratio indicating decreased severity of widespread hyperalgesia. Normalized ratio=heat pain threshold at tibialis anterior/heat pain threshold at upper arm Normalized ratio=heat pain threshold at tibialis anterior/heat pain threshold at lateral trunk Unit of the outcome measure is centigrade degree. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery.

    Time frame: Time frame up to 12 months post-surgery

  13. Efficacy of inhibitory pain mechanism

    A cold pressure test is performed to test the efficacy of inhibitory pain mechanism. The test (pressure pain threshold on the non-affected tibialis anterior muscle) and conditioning stimulus (cold stimulus on non-affected hand) is applied. The non-affected hand is immersed in a cold water bath of 12 centigrade degree for 60 seconds. 30 and 60 seconds after the application of the conditioning stimulus, the first and second test stimulus (pain pressure thresholds) is measured at the non-affected tibialis anterior muscle. The difference between second and first test stimulus is calculated and used for the analysis. Unit of the outcome measure is kilogram per square centimeter (kg/cm2). Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery.

    Time frame: Time frame up to 12 months post-surgery

  14. Degree of pain facilitation

    This measurement is performed using a 26 g monofilament. Repetitive 30 stimuli will be applied at affected lateral trunk. Perceived intensity of stimulus will be assessed between 0 and 10. Pain intensity scores are recorded on the Numerical Rating Scale after the first stimuli and after 30 consecutive stimuli (65). Difference between Numerical Rating Scale after 30 stimuli and the first stimulus is calculated and used for the analysis. Score is between 0 - 10. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  15. Severity of altered body perception

    Body perception is evaluated by the Fremantle Upper Limb Awareness Questionnaire. This questionnaire evaluates neglect-like symptoms, reduced sensory acuity, and perceived size at arm and trunk/breast and consists of 9 items. Each item is scored on a 5-point Likert scale from 0 (never) to 4 (always). Higher scores indicate a greater sense of bodily unawareness in the affected arm or trunk/breast. Total score ranges between 0 - 63. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery.

    Time frame: Time frame up to 12 months post-surgery

  16. Severity of subjective arm lymphedema

    Severity of subjective arm lymphedema is determined based on the severity of the difference in the size of 3 sites (hand, lower arm, and upper arm) by two items: 1) frequency with "0: not applicable to 4: almost always" and 2) severity with "0: not applicable to 3: very noticeable". Total score ranges between 0 and 21. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery

    Time frame: Time frame up to 12 months post-surgery

  17. Severity of subjective trunk lymphedema

    The severity of subjective trunk BCRL will be determined by the severity of the difference in the size of trunk and breast/ breast region by two items: 1) frequency with "0: not applicable to 4: almost always" and 2) severity with "0: not applicable to 3: very noticeable". Total score is between 0 and 14. Assessment at pre-surgery (baseline) and 1 month, 6 months, and 12 months post-surgery.

    Time frame: Time frame up to 12 months post-surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gursen C, Dylke ES, Moloney N, Meeus M, De Vrieze T, Devoogdt N, De Groef A. Self-reported signs and symptoms of secondary upper limb lymphoedema related to breast cancer treatment: Systematic review. Eur J Cancer Care (Engl). 2021 Sep;30(5):e13440. doi: 10.1111/ecc.13440. Epub 2021 Mar 18. PubMed 33733550 ↗
  • Svensson BJ, Dylke ES, Ward LC, Black DA, Kilbreath SL. Screening for breast cancer-related lymphoedema: self-assessment of symptoms and signs. Support Care Cancer. 2020 Jul;28(7):3073-3080. doi: 10.1007/s00520-019-05083-7. Epub 2019 Oct 22. PubMed 31641870 ↗
  • De Groef A, Devoogdt N, Gursen C, Moloney N, Warpy V, Daelemans J, Dams L, Haenen V, Van der Gucht E, Heroes AK, De Vrieze T, Dylke E. Correction to: Sensory signs and symptoms in women with self-reported breast cancer-related lymphedema: a case-control study. J Cancer Surviv. 2022 Dec;16(6):1508-1509. doi: 10.1007/s11764-021-01125-4. No abstract available. PubMed 34716888 ↗
  • Fu MR, Axelrod D, Cleland CM, Qiu Z, Guth AA, Kleinman R, Scagliola J, Haber J. Symptom report in detecting breast cancer-related lymphedema. Breast Cancer (Dove Med Press). 2015 Oct 15;7:345-52. doi: 10.2147/BCTT.S87854. eCollection 2015. PubMed 26527899 ↗
  • Sackey H, Johansson H, Sandelin K, Liljegren G, MacLean G, Frisell J, Brandberg Y. Self-perceived, but not objective lymphoedema is associated with decreased long-term health-related quality of life after breast cancer surgery. Eur J Surg Oncol. 2015 Apr;41(4):577-84. doi: 10.1016/j.ejso.2014.12.006. Epub 2015 Jan 13. PubMed 25659877 ↗
  • Terada M, Yoshimura A, Sawaki M, Hattori M, Naomi G, Kotani H, Adachi Y, Iwase M, Kataoka A, Sugino K, Mori M, Horisawa N, Ozaki Y, Iwata H. Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors. Breast Cancer Res Treat. 2020 Jan;179(1):91-100. doi: 10.1007/s10549-019-05443-1. Epub 2019 Sep 18. PubMed 31535321 ↗
  • Sayko O, Pezzin LE, Yen TW, Nattinger AB. Diagnosis and treatment of lymphedema after breast cancer: a population-based study. PM R. 2013 Nov;5(11):915-23. doi: 10.1016/j.pmrj.2013.05.005. Epub 2013 May 17. PubMed 23684778 ↗
  • McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol. 2008 Nov 10;26(32):5220-6. doi: 10.1200/JCO.2008.16.3766. Epub 2008 Oct 6. PubMed 18838708 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for May 2027, 38 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 38 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 22, 2024
StartActual
Mar 26, 2024
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06324721
Responsible party
Nele Devoogdt (Prof. Dr., Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Mar 22, 2024
Start date
Mar 26, 2024
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 29, 2025

Study contacts

Nele Devoogdt, Prof. Dr.
Contact
nele.devoogdt@uzleuven.be
003216342515
Ceren Gursen, Dr
Contact
ceren.guersen@kuleuven.be
003216325815
Nele Devoogdt, Prof. Dr.
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion